Cryptococcal Meningitis (Cryptococcus neoformans)
Overview
Plain-Language Overview
Cryptococcal Meningitis is a serious infection that affects the brain and spinal cord, caused by the fungus Cryptococcus neoformans. This infection primarily impacts the central nervous system, leading to inflammation of the protective membranes around the brain and spinal cord, known as the meninges. It most commonly occurs in people with weakened immune systems, such as those with HIV/AIDS. Symptoms often include headache, fever, neck stiffness, and confusion. If untreated, it can cause severe neurological damage or death. Diagnosis requires specialized tests to detect the fungus in the spinal fluid. Treatment involves powerful antifungal medications to control the infection.
Clinical Definition
Cryptococcal Meningitis is a life-threatening fungal infection characterized by inflammation of the meninges caused by the encapsulated yeast Cryptococcus neoformans. It predominantly affects immunocompromised patients, especially those with CD4+ T-cell depletion such as in HIV/AIDS or organ transplant recipients on immunosuppressants. The fungus enters the central nervous system via hematogenous spread after inhalation of spores, leading to meningeal inflammation and increased intracranial pressure. Clinical features include subacute headache, fever, neck stiffness, altered mental status, and sometimes cranial nerve palsies. The infection is notable for its ability to evade host immunity through a polysaccharide capsule and melanin production. Without prompt diagnosis and treatment, it can cause meningoencephalitis, hydrocephalus, and death.
Inciting Event
Inhalation of Cryptococcus neoformans spores from environmental sources initiates infection.
Exposure to bird droppings or contaminated soil is the typical environmental trigger.
Reactivation of latent infection can occur in immunosuppressed patients leading to CNS disease.
Disruption of blood-brain barrier facilitates fungal entry into the meninges.
Recent initiation or escalation of immunosuppressive therapy can precipitate symptomatic disease.
Latency Period
Variable latency from weeks to months between inhalation and symptom onset is common.
In immunocompromised patients, progression to meningitis can be rapid within days to weeks.
In immunocompetent hosts, latency may be prolonged with subacute or chronic symptoms.
Reactivation disease may occur months to years after initial exposure.
Delayed diagnosis often reflects slow symptom progression and nonspecific early signs.
Diagnostic Delay
Nonspecific symptoms such as headache and fever often mimic viral or bacterial meningitis, delaying suspicion.
Low index of suspicion in non-HIV patients leads to missed early diagnosis.
Limited access to cryptococcal antigen testing or lumbar puncture in resource-poor settings causes delays.
Misinterpretation of cerebrospinal fluid findings as viral meningitis can postpone antifungal treatment.
Overlap with other opportunistic infections in immunocompromised hosts complicates diagnosis.
Clinical Presentation
Signs & Symptoms
Headache is the most common presenting symptom due to meningeal inflammation and increased intracranial pressure.
Fever is present in most patients but may be subtle in immunocompromised hosts.
Neck stiffness reflects meningeal irritation.
Photophobia and nausea/vomiting are common due to meningeal involvement.
Altered mental status including confusion, lethargy, or coma occurs in advanced disease.
History of Present Illness
Gradual onset of headache, fever, and malaise over days to weeks is typical.
Progressive neurological symptoms including neck stiffness, photophobia, and altered mental status develop as meningitis worsens.
Nausea, vomiting, and cranial nerve palsies may occur due to increased intracranial pressure.
Subacute cognitive decline or personality changes can be presenting features in chronic cases.
Respiratory symptoms may precede CNS manifestations if pulmonary infection is present.
Past Medical History
Known HIV infection with low CD4 count or AIDS diagnosis is highly relevant.
History of organ transplantation or chronic immunosuppressive therapy increases risk.
Previous opportunistic infections or fungal infections suggest immunodeficiency.
Chronic illnesses such as diabetes or malignancy may predispose to infection.
Prior exposure to environments with bird droppings or soil contaminated with Cryptococcus spores.
Family History
[]
Physical Exam Findings
Nuchal rigidity indicating meningeal irritation is a common finding in cryptococcal meningitis.
Altered mental status ranging from confusion to coma may be observed in advanced cases.
Fever is frequently present but may be low-grade or absent in immunocompromised patients.
Papilledema may be seen due to increased intracranial pressure.
Focal neurological deficits such as cranial nerve palsies can occur with basal meningeal involvement.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of cryptococcal meningitis is established by detecting Cryptococcus neoformans in cerebrospinal fluid (CSF) obtained via lumbar puncture. Key findings include positive India ink stain showing encapsulated yeast, elevated CSF opening pressure, lymphocytic pleocytosis, and low CSF glucose. The cryptococcal antigen test in CSF or serum is highly sensitive and specific for confirming infection. Fungal culture of CSF provides definitive diagnosis but takes longer. Neuroimaging may show meningeal enhancement or hydrocephalus but is not diagnostic.
Pathophysiology
Key Mechanisms
Inhalation of airborne Cryptococcus neoformans spores leads to pulmonary infection and hematogenous dissemination to the central nervous system.
Polysaccharide capsule of Cryptococcus neoformans inhibits phagocytosis and promotes immune evasion.
Meningeal invasion causes inflammation and increased intracranial pressure, leading to neurological symptoms.
Impaired cell-mediated immunity, especially defective T-cell responses, allows uncontrolled fungal proliferation in the CNS.
Formation of cryptococcomas and gelatinous pseudocysts disrupts normal brain architecture and function.
| Involvement | Details |
|---|---|
| Organs | Brain is the primary organ affected, with cryptococcal invasion causing meningoencephalitis and increased intracranial pressure |
Lungs serve as the initial site of Cryptococcus neoformans inhalation and primary infection before dissemination | |
| Tissues | Meninges are inflamed in cryptococcal meningitis, leading to symptoms of headache, neck stiffness, and altered mental status |
| Cells | Macrophages phagocytose Cryptococcus neoformans but may serve as a reservoir for fungal persistence |
T lymphocytes mediate adaptive immune response critical for fungal clearance, especially CD4+ cells | |
Neutrophils contribute to initial innate immune response but are less effective against encapsulated fungi | |
| Chemical Mediators | Interferon-gamma enhances macrophage fungicidal activity and is important for controlling cryptococcal infection |
Tumor necrosis factor-alpha promotes inflammatory response and granuloma formation in cryptococcal meningitis | |
Cryptococcal polysaccharide capsule antigen is a key virulence factor and diagnostic marker detected in cerebrospinal fluid |
Treatments
Pharmacological Treatments
Amphotericin B
- Mechanism:
Binds ergosterol in fungal cell membranes causing pore formation and cell death
- Side effects:
Nephrotoxicity
Infusion-related reactions
Electrolyte imbalances
- Clinical role:
First-line
Flucytosine
- Mechanism:
Inhibits fungal DNA and RNA synthesis by conversion to 5-fluorouracil inside fungal cells
- Side effects:
Bone marrow suppression
Gastrointestinal upset
Hepatotoxicity
- Clinical role:
First-line adjunctive
Fluconazole
- Mechanism:
Inhibits fungal cytochrome P450 enzyme 14-alpha-demethylase, impairing ergosterol synthesis
- Side effects:
Hepatotoxicity
QT prolongation
Gastrointestinal upset
- Clinical role:
Long-term control
Non-pharmacological Treatments
Therapeutic lumbar puncture to reduce elevated intracranial pressure and prevent neurological complications
Prevention
Pharmacological Prevention
Fluconazole prophylaxis is recommended in HIV patients with CD4 counts <100 cells/mm3 to prevent cryptococcal meningitis.
Primary antifungal prophylaxis is used in high-risk immunocompromised populations such as transplant recipients.
Secondary prophylaxis with fluconazole is indicated after initial cryptococcal meningitis treatment to prevent relapse.
Non-pharmacological Prevention
Avoidance of exposure to environments rich in bird droppings, especially pigeon guano, which harbor Cryptococcus neoformans.
Early HIV diagnosis and antiretroviral therapy to maintain immune function and prevent opportunistic infections.
Regular screening for cryptococcal antigenemia in high-risk HIV patients to enable preemptive treatment.
Minimizing immunosuppressive therapy when possible in transplant and autoimmune patients.
Outcome & Complications
Complications
Increased intracranial pressure leading to brain herniation is a major cause of mortality.
Hydrocephalus may develop from impaired CSF flow.
Cranial nerve palsies due to basal meningeal inflammation.
Seizures can occur secondary to cortical irritation or cryptococcomas.
Immune reconstitution inflammatory syndrome (IRIS) may complicate treatment in HIV patients starting antiretroviral therapy.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Cryptococcal Meningitis (Cryptococcus neoformans) versus Tuberculous Meningitis
Cryptococcal Meningitis (Cryptococcus neoformans) | Tuberculous Meningitis |
|---|---|
Subacute onset with more rapid progression over days to weeks | Subacute to chronic progression over weeks with gradual worsening |
Lymphocytic pleocytosis with moderately low glucose and elevated protein | Lymphocytic pleocytosis with very low glucose and high protein |
Dilated perivascular spaces and gelatinous pseudocysts without mass lesions | Basal meningeal enhancement with possible tuberculomas |
Positive India ink stain or cryptococcal antigen test | Positive acid-fast bacilli stain or PCR for Mycobacterium tuberculosis |
Cryptococcal Meningitis (Cryptococcus neoformans) versus Bacterial Meningitis (e.g., Streptococcus pneumoniae)
Cryptococcal Meningitis (Cryptococcus neoformans) | Bacterial Meningitis (e.g., Streptococcus pneumoniae) |
|---|---|
Predominantly lymphocytic pleocytosis | Predominantly neutrophilic pleocytosis |
Subacute onset with slower progression over days to weeks | Acute onset with rapid progression over hours to days |
Moderately decreased glucose | Markedly decreased glucose (<40 mg/dL) |
Requires antifungal therapy with amphotericin B and flucytosine | Rapid improvement with empiric intravenous antibiotics |
Cryptococcal Meningitis (Cryptococcus neoformans) versus Viral (Aseptic) Meningitis
Cryptococcal Meningitis (Cryptococcus neoformans) | Viral (Aseptic) Meningitis |
|---|---|
Decreased glucose concentration | Normal glucose concentration |
Lymphocytic pleocytosis with higher protein elevation | Lymphocytic pleocytosis with lower protein elevation |
Progressive without treatment, requiring antifungal therapy | Self-limited course with spontaneous resolution in 7-10 days |
Cryptococcal Meningitis (Cryptococcus neoformans) versus Neurosyphilis
Cryptococcal Meningitis (Cryptococcus neoformans) | Neurosyphilis |
|---|---|
Exposure to environments contaminated with bird droppings or soil | History of untreated syphilis or high-risk sexual behavior |
Positive cryptococcal antigen and India ink stain | Lymphocytic pleocytosis with positive VDRL test in CSF |
Subacute meningitis symptoms developing over days to weeks | Chronic progressive neurological symptoms over months to years |
Cryptococcal Meningitis (Cryptococcus neoformans) versus CNS Lymphoma (Primary or Secondary)
Cryptococcal Meningitis (Cryptococcus neoformans) | CNS Lymphoma (Primary or Secondary) |
|---|---|
Diffuse meningeal enhancement or dilated perivascular spaces without mass | Focal enhancing mass lesions with surrounding edema |
CSF positive for cryptococcal antigen or yeast on India ink | Biopsy showing malignant lymphoid cells |
Commonly occurs in immunocompromised with meningeal infection pattern | Often occurs in immunocompromised patients but may present with mass lesions |